Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Interactive Journal of Medical Research

Date Submitted: Jul 28, 2023
Date Accepted: May 20, 2024

The final, peer-reviewed published version of this preprint can be found here:

Research Trends and Evolution in Radiogenomics (2005-2023): Bibliometric Analysis

Wang M, Peng Y, Wang Y, Luo D

Research Trends and Evolution in Radiogenomics (2005-2023): Bibliometric Analysis

Interact J Med Res 2024;13:e51347

DOI: 10.2196/51347

PMID: 38980713

PMCID: 11267093

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Frontiers and Hotspots Evolution of radiogenomics from 2005 to 2023: A bibliometric analysis

  • Meng Wang; 
  • Yun Peng; 
  • Ya Wang; 
  • Dehong Luo

ABSTRACT

Background:

Radiogenomics has emerged as a field that links medical imaging (radiomics) with molecular pathology (genomics), including proteomics and metabolomics. It utilizes radiomics to improve disease diagnosis, predict prognosis, evaluate treatment efficacy, and analyze outcomes. This study aims to examine the current research status and highlight the dynamic changes in hotspots within radiogenomics research.

Objective:

Radiogenomics has emerged as a field that links medical imaging (radiomics) with molecular pathology (genomics), including proteomics and metabolomics. It utilizes radiomics to improve disease diagnosis, predict prognosis, evaluate treatment efficacy, and analyze outcomes. This study aims to examine the current research status and highlight the dynamic changes in hotspots within radiogenomics research.

Methods:

Visual software Vosviewer and Citespace were employed to analyze the data in this study. Vosviewer was used to assess the frequency of keywords, while Citespace was utilized to analyze countries, institutions, journals, co-citations, reference clusters, timeline views, and keyword bursts. The number of published documents was counted using Excel.

Results:

The United States and China are the leading contributors to this field, with the largest number of co-citations and published articles, respectively. The co-occurrence map of keywords indicates a recent prevalence of machine learning, deep learning, and artificial intelligence. The reference co-citations resulted in 11 clusters, including radiomics, glioma, breast cancer, EGFR, radiotherapy, normal tissue toxicity, glioblastoma, rectal cancer, immunotherapy, oncologic imaging, and deep learning.

Conclusions:

The United States and China are the leading contributors to this field, with the largest number of co-citations and published articles, respectively. The co-occurrence map of keywords indicates a recent prevalence of machine learning, deep learning, and artificial intelligence. The reference co-citations resulted in 11 clusters, including radiomics, glioma, breast cancer, EGFR, radiotherapy, normal tissue toxicity, glioblastoma, rectal cancer, immunotherapy, oncologic imaging, and deep learning.


 Citation

Please cite as:

Wang M, Peng Y, Wang Y, Luo D

Research Trends and Evolution in Radiogenomics (2005-2023): Bibliometric Analysis

Interact J Med Res 2024;13:e51347

DOI: 10.2196/51347

PMID: 38980713

PMCID: 11267093

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.